Date: 2012-07-09
Type of information: Commercialisation agreement
Compound: episil® (mixture of soy phospholipid (lecithin) and glycerol dioleate)
Company: Camurus (Sweden) Cangene (Canada)
Therapeutic area: Cancer - Oncology - CNS diseases
Type agreement: commercialisation
Action mechanism: episil® is administered as a lipid-based liquid that spreads on the intra-oral mucosal surfaces and transforms to a strongly bioadhesive FluidCrystal film that mechanically protects the sensitized and sore epithelium of the oral cavity. episil® has been clinically demonstrated to reduce pain for up to eight hours following administration. episil® was developed by Camurus AB, a privately owned Swedish life science company. It is cleared as a medical device in the United States and in Europe.
Disease: management and relief of pain associated with oral lesions, including oral mucositis (OM), which results from cancer therapy and other causes
Details: Cangene and Camurus have entered into an agreement under which Cangene bioPharma Inc., a wholly-owned subsidiary of Cangene, will have exclusive rights to commercialize episil® in the United States for the management and relief of pain associated with oral lesions, including oral mucositis (OM), which results from cancer therapy and other causes. Cangene bioPharma plans to launch episil® in the United States in October 2012.
episil® has been clinically demonstrated to reduce pain for up to 8 hours. The product is supplied as a ready-to-use, pocket-sized device, helping patients maintain their quality of life while undergoing cancer therapy.
Financial terms:
Latest news:
